JP2023520927A5 - - Google Patents

Info

Publication number
JP2023520927A5
JP2023520927A5 JP2022561477A JP2022561477A JP2023520927A5 JP 2023520927 A5 JP2023520927 A5 JP 2023520927A5 JP 2022561477 A JP2022561477 A JP 2022561477A JP 2022561477 A JP2022561477 A JP 2022561477A JP 2023520927 A5 JP2023520927 A5 JP 2023520927A5
Authority
JP
Japan
Prior art keywords
sequence
dnaj
fusion protein
polyglutamine
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/026633 external-priority patent/WO2021207636A2/en
Publication of JP2023520927A publication Critical patent/JP2023520927A/ja
Publication of JP2023520927A5 publication Critical patent/JP2023520927A5/ja
Pending legal-status Critical Current

Links

JP2022561477A 2020-04-10 2021-04-09 タンパク質凝集障害の処置のための組成物および方法 Pending JP2023520927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063008251P 2020-04-10 2020-04-10
US63/008,251 2020-04-10
PCT/US2021/026633 WO2021207636A2 (en) 2020-04-10 2021-04-09 Compositions and methods for the treatment of protein aggregation disorders

Publications (2)

Publication Number Publication Date
JP2023520927A JP2023520927A (ja) 2023-05-22
JP2023520927A5 true JP2023520927A5 (cg-RX-API-DMAC7.html) 2024-03-27

Family

ID=75747121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561477A Pending JP2023520927A (ja) 2020-04-10 2021-04-09 タンパク質凝集障害の処置のための組成物および方法

Country Status (10)

Country Link
US (1) US20230226223A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132955A2 (cg-RX-API-DMAC7.html)
JP (1) JP2023520927A (cg-RX-API-DMAC7.html)
KR (1) KR20220167324A (cg-RX-API-DMAC7.html)
CN (1) CN115667289A (cg-RX-API-DMAC7.html)
AU (1) AU2021254272A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020444A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022012525A (cg-RX-API-DMAC7.html)
TW (1) TW202204383A (cg-RX-API-DMAC7.html)
WO (1) WO2021207636A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057858B (zh) 2020-08-10 2023-03-21 上海瑞吉康生物医药有限公司 对引起神经变性和神经退行性疾病的蛋白聚集具有解聚作用的多肽
AU2021367952A1 (en) * 2020-10-26 2023-06-08 Sola Biosciences Llc Compositions and methods for the treatment of alzheimer's disease
EP4686478A1 (en) * 2024-07-31 2026-02-04 Consejo Superior de Investigaciones Científicas (CSIC) Qbp1 for use in the treatment and/or prevention of type 2 diabetes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP1002119A1 (en) 1997-07-31 2000-05-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeted hsv vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US7465583B2 (en) 2000-06-01 2008-12-16 The University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
JP2008125455A (ja) * 2006-11-22 2008-06-05 Sapporo Medical Univ ポリグルタミン凝集体形成阻害活性を有するポリペプチド
US20100016221A1 (en) * 2008-07-17 2010-01-21 Riken Method of degrading protein by chaperone-mediated autophagy
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
WO2011097456A2 (en) 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
WO2011140315A2 (en) * 2010-05-05 2011-11-10 Northwestern University Method of reducing proteins misfolding and/or aggregation
WO2014053879A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP2929045B1 (en) * 2012-12-05 2020-12-02 SOLA Biosciences LLC Protein expression enhancing polypeptides
WO2018058088A1 (en) * 2016-09-26 2018-03-29 SOLA Biosciences, LLC Cell-associated secretion-enhancing fusion proteins

Similar Documents

Publication Publication Date Title
JP7374119B2 (ja) 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
JP2023524414A5 (cg-RX-API-DMAC7.html)
JP7801093B2 (ja) 細胞トランスフェクション及び/又はrAAVベクター産生の改善のための増強剤
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP6619454B2 (ja) キャプシド
JP2021512649A5 (cg-RX-API-DMAC7.html)
Mori et al. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein
ES2230569T3 (es) Funciones accesorias para uso en la produccion de viriones aav recombinantes.
Lu Recombinant adeno-associated virus as delivery vector for gene therapy—a review
JP2023529371A5 (cg-RX-API-DMAC7.html)
JP2022508182A5 (cg-RX-API-DMAC7.html)
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
TW201629225A (zh) 第九因子基因療法
JP2023537358A5 (cg-RX-API-DMAC7.html)
US20260009048A1 (en) System for High-Level rAAV Production
US11780886B2 (en) Modified viral vectors and methods of making and using the same
Nóbrega et al. Viral vectors for gene therapy
JP2023541444A5 (cg-RX-API-DMAC7.html)
JP2022542829A5 (cg-RX-API-DMAC7.html)
JP2018536432A5 (cg-RX-API-DMAC7.html)
US10105450B2 (en) Promoter compositions
JP2020533313A5 (cg-RX-API-DMAC7.html)
RU2021117249A (ru) Модулирующие полинуклеотиды
JP2023548632A5 (cg-RX-API-DMAC7.html)
Stiefelhagen et al. 865. Focus on Specificity: Creating Efficient CML-Specific Recombinant Adeno-Associated Viral (AAV) Vectors Using a Random Peptide Library